Cue Biopharma, Inc.

NasdaqCM:CUE Rapporto sulle azioni

Cap. di mercato: US$65.3m

Cue Biopharma Salute del bilancio

Salute finanziaria criteri di controllo 3/6

Cue Biopharma ha un patrimonio netto totale di $25.4M e un debito totale di $5.3M, che porta il suo rapporto debito/patrimonio netto a 20.9%. Le sue attività totali e le sue passività totali sono rispettivamente $44.8M e $19.4M.

Informazioni chiave

20.9%

Rapporto debito/patrimonio netto

US$5.29m

Debito

Indice di copertura degli interessin/a
ContantiUS$32.42m
Patrimonio nettoUS$25.37m
Totale passivitàUS$19.44m
Totale attivitàUS$44.81m

Aggiornamenti recenti sulla salute finanziaria

Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money

Apr 16
Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money

Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?

Dec 30
Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?

Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?

Aug 11
Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?

Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

Sep 23
Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

Recent updates

Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money

Apr 16
Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money

Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?

Dec 30
Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?

Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?

Aug 11
Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?

Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug

Oct 04

Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

Sep 23
Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat

Aug 26
News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat

Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates

Aug 10
Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates

Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%

May 18
Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%

Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

May 12
Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Cue Biopharma: A First Assessment

May 11

Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Mar 19
Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Cue Biopharma: Too Long To Arrive At Topline Trial Data

Feb 23

We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth

Nov 04
We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $37.3M ) di CUE superano le sue passività a breve termine ( $16.8M ).

Passività a lungo termine: Le attività a breve termine di CUE ( $37.3M ) superano le sue passività a lungo termine ( $2.7M ).


Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: CUE ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di CUE è aumentato da 0% a 20.9% negli ultimi 5 anni.


Bilancio


Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: CUE ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: CUE ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 7.1 % ogni anno


Scoprire le aziende sane